[1] Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Bio, 2004, 5(10): 836–847.
[2] Fausto N, Campbell JS, Riehle KJ. Liver regeneration. HepatologY, 2006, 43(2): S45–53.
[3] Michalopoulos GK, DeFrances M. Liver regeneration. Science, 1997, 276(5309): 60–66.
[4] Yuan YS, Wu XY, Ou QX, Gao J, Han W, Tennant, BC, and Yu Y. Differential expression of the genes involved in amino acids and nitrogen metabolisms during liver regeneration of mice. Hepatol Res, 39(3): 301–312.
[5] Ozaki M. Role of Jak/STAT 3 and PI3-K/Akt pathways in liver injury and regeneration. Seikagaku, 2008, 80(5): 399–408.
[6] Diehl AM, Rai R. Review: Regulation of liver regenera-tion by proinflammatory cytoklnes. J Gastroenterol Hepaml, 1996, 11(5): 466–470.
[7] Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor. Proc Natl Acad Sci USA, 1997, 94(4): 144–146.
[8] Wang B, Gao C, Ponder KP. C/EBPbeta contributes to hepatocyte growth factor-induced replication of rodent heaptocytes. Jhepatol, 2005, 43(2): 294–302.
[9] Bruccoleri A, Galhcci R, Germolec DR, Blackshear P. In-duction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatolngy, 1997, 25(1): 133–141.
[10] Castro GD, Díaz Gómez MI, Castro JA. DNA bases attack by reactive metabolites produced during carbon tetrachlo-ride biotransformation and promotion of liver microsomal lipid peroxidation. Res Commun Mol Pathol Pharmacol, 1997, 95: 253–258.
[11] Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbontetrachloride as a toxicological model. Crit Rev Toxicol, 2003, 33(2): 105–136.
[12] Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol, 2008, 20(2): 183–189.
[13] Cuschieri J, Maier RV. Mitogen-activated protein kinase (MAPK). Crit Care Med, 2005, 33(12): 417–441.
[14] Punn A, Mockridge JW, Farooqui S, Marber MS, Heads RJ. Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes. Biochem J, 2000, 350(Pt 3): 891–899.
[15] Lee JT Jr, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic in-tervention in leukemia. Leukemia, 2002, 16(4): 486–507.
[16] Kyriakis J M, Avruch J. Mammalian mitogen-activated pro-tein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev, 2001, 81(2): 807–869.
[17] Simon JA, Schreiber SI. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. Chem Biol, 1995, 2(1): 53–60.
[18] Gao J, Li WX, Feng SQ, Wan DF, Han W, Yu Y. A protein- protein interaction network of transcription factors acting during liver cell proliferation. Genomics, 91(4): 347–355.
[19] Feller SM, Tuchscherer G, Voss J. High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronicmyelogenous leukaemia. Leuk Lymphoma, 2003, 44(3): 411–427.
[20] Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Es-trov Z, Talpaz M, Arlinghaus RB, Feller SM. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SOS complexes. Blood, 2001, 98(6): 1773–1781.
[21] Jun N, Kazuya K1, Atsushi H, Jun-ichiro I, Zhaodan C, Kunihiro M. The kinase TAK1 can activate the NIK-IB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature, 1999, 398(6724): 252–256.
[22] Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, Ninomiya-Tsuji J, Matsumoto K. TAB2, a novel adaptor protein,mediates activa |